MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Matinas BioPharma Holdings Operating Expenses 2011-2026 | MTNB
Annual Operating Expenses Matinas BioPharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 24.4 M | 19 M | 14.8 M | 16.7 M | 8.26 M | 10.1 M | 10.5 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.4 M | 8.26 M | 14.8 M |
Quarterly Operating Expenses Matinas BioPharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.45 M | 4.02 M | 4.5 M | - | 1.84 M | 1.62 M | 2.24 M | - | 2.22 M | 2.48 M | 2.63 M | - | 2.61 M | 2.42 M | 2.13 M | - | 1.45 M | 343 K | 112 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.5 M | 112 K | 2.27 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Verastem
VSTM
|
147 M | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
56.5 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
279 M | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
1.09 B | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
101 M | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
156 M | - | 0.42 % | $ 213 M | USA |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
201 M | - | - | - | Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Teligent, Inc.
TLGT
|
548 K | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
163 M | - | - | $ 2.91 B | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
640 M | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
172 M | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
12.8 B | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |